Roy T. Steigbigel

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 686 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

David A. Cooper, Roy T. Steigbigel, José M. Gatell et al. · New England Journal of Medicine · 2008 · 507 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +14

Method of reliable determination of minimal lethal antibiotic concentrations

Richard D. Pearson, Roy T. Steigbigel, H T Davis et al. · Antimicrobial Agents and Chemotherapy · 1980 · 450 citations · Full text

Life Sciences, Microbiology, Antimicrobial Pharmacology +12

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Jon H. Condra, Daniel Holder, William A. Schleif et al. · Journal of Virology · 1996 · 405 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

Martin Markowitz, Javier O Morales-Ramirez, Bach‐Yen Nguyen et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 366 citations

Pharmacy, Pharmacokinetics, Pharmacology +17